James Noble
CIK 1388000 · Chief Executive Officer · last filed 2025-11-17
James Noble is a Chief Executive Officer who has filed 28 SEC Form 4 insider transactions across 6 companies since 2007. The most recent filing, for LVTX, was dated Nov 17, 2025. Across all open-market trades the lifetime net is −$7.3M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $386.6M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$386.64M
6
28
-$7.27M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LAVA Therapeutics NV (LVTX) Delisted | Director | — | $1.74 | — | $0 | 2 | 2025-11-17 |
| Adaptimmune Therapeutics PLC (ADAP) Delisted | Director | 0 | $0.06 | $0 | -$6.07M | 7 | 2022-07-01 |
| GW PHARMACEUTICALS PLC (GWPH) Delisted | Director | 41,300 | $218.96 | $9.04M | -$1.27M | 4 | 2021-02-24 |
| ASND | Chief Executive Officer | 1,773,100 | $218.06 | $386.64M | $0 | 4 | 2019-05-17 |
| STRATA Skin Sciences, Inc. (MELA) Delisted | Director | — | — | — | $0 | 1 | 2012-01-06 |
| CURAGEN CORP (CRGN) Delisted | Director | 20,000 | — | — | $57.4K | 7 | 2009-05-14 |
Recent Filings
28 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-11-17 | LAVA Therapeutics NV (LVTX) Delisted | Disp (D) | — | $0 | EDGAR |
| 2025-02-18 | LAVA Therapeutics NV (LVTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-07-01 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-07-02 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-05-07 | — | Disp (D) | −27,492 | $0 | |
| 2021-02-24 | GW PHARMACEUTICALS PLC (GWPH) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-07-01 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-06-08 | GW PHARMACEUTICALS PLC (GWPH) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-06-02 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Sell (S) | −500,000 | -$4.67M | EDGAR |
| 2020-04-01 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Grant (A) | — | $0 | EDGAR |